Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,490 across all filing types
Latest filing 2024-11-01 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, and confirms no changes in warrants, convertibles, or other agreements to issue shares. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and shareholding movements. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing reporting share capital and share movements as required by exchange rules. The document length is 6636 characters, containing detailed data rather than a brief announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-11-01 English
VOLUNTARY ANNOUNCEMENT SHENYANG SUNSHINE HAS ENTERED INTO A COOPERATION AGREEMENT WITH HAIHE BIOPHARMA IN RESPECT OF PACLITAXEL ORAL SOLUTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding entering into a cooperation agreement for commercialization rights of a pharmaceutical product. It is an announcement of a business cooperation agreement, not a financial report, regulatory filing, or management change. The document is short (2223 characters) and does not contain financial data, audit information, or voting results. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category for miscellaneous filings that do not fit other specific categories.
2024-10-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2024. It details movements in authorised share capital, issued shares, treasury shares, share options, and confirms no changes in warrants, convertibles, or other arrangements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and shareholding movements. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory compliance filing focused on share capital movements and share options. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorised/registered share capital, issued shares, treasury shares, and related confirmations for the month ended 30 September 2024. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes no financial statements or earnings data. The content is regulatory in nature, reporting share capital and share movements, but does not announce a new share issue or capital change event. It is a regulatory compliance filing related to share capital movements under the Exchange Listing Rules. Given the detailed nature and regulatory context, but absence of a direct capital change event announcement, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-02 English
2024 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 2024' and contains detailed financial highlights, management discussion and analysis, corporate information, governance details, and interim condensed consolidated financial statements such as statement of profit or loss, comprehensive income, financial position, changes in equity, and cash flows. The presence of an Independent Review Report and detailed notes to interim condensed consolidated financial information further supports this. The reporting period is the six months ended 30 June 2024, indicating a half-year financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-09-30 English
Notification Letter and Request Form to Non-registered Holders - Notice of publication of 2024 Interim Report
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 30 September 2024 from Hongkong Chinese Limited informing non-registered shareholders about the publication of the company's 2024 Interim Report. It provides instructions on how to access the report online and how to request a printed copy. The letter explicitly states that the Interim Report is available on the company's and the stock exchange's websites and offers a request form for printed copies. The document does not contain the actual interim financial statements or substantive financial data but is rather an announcement of the report's availability. The document length is 5652 characters, which is relatively short and consistent with a notification letter rather than a full interim report. According to the "Menu vs Meal" rule, this is a Report Publication Announcement (RPA) rather than the Interim Report itself.
2024-09-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.